Vertex Pharmaceuticals Incorporated (VRTX) Stock: Price, Forecast & Analyst Target
Vertex Pharmaceuticals Incorporated (VRTX) — MoonshotScore 90/100 (Exceptional band), calculated Nov 18, 2026. Price $536.45 (+0.42%), as of the Nov 18, 2026 trading session; market cap $136B. Expected results Feb 11, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Vertex Pharmaceuticals Incorporated · VRTX · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-12: Vertex is a commercial rare-disease drugmaker whose profits still come overwhelmingly from cystic fibrosis treatments, especially Trikafta and Kaftrio. The case rests on whether medicines such as Alyftrek and Casgevy can broaden that earnings base while preserving the unusually strong economics of the cystic fibrosis franchise.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · Vertex Pharmaceuticals (VRTX)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality, a strong balance sheet and durable growth, but an expensive valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Sound; Valuation: Rich; Growth Durability: Compounding; Momentum: Surging.
- EPS beat 0 of the last 4 reports
- expected results Feb 11, 2027
- Altman Z 8.68 · Piotroski F 4
Helping: business quality, balance-sheet strength, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 94 | Exceptional | |
| 94 | Exceptional | |
| 94 | Exceptional | |
| 94 | Exceptional | |
| 90 | Exceptional | |
| 90 | Exceptional |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $536.45 | |
| Change on the day | +0.42% | |
| 52-week range | $412.27–$568.67 | |
| Market capitalisation | $136B | — |
| Price / earnings (trailing) | 34.11 | |
| Shares traded on the day | 1.29M | |
| Beta (volatility vs the S&P 500) | 0.32 |
Why Vertex Pharmaceuticals scores 90
Share price, last 12 months +30.8%
$421.20 $550.87
What the price assumes
17.7% a year of free-cash-flow growth for ten years is what a $139.62B market value ( snapshot) asks for.
The price already assumes faster growth than the last 5 years delivered. Anything short of an acceleration leaves room to disappoint. It also runs ahead of the analysts' revenue path.
Reverse discounted cash flow: 10% discount rate, 3% growth after year ten, starting from trailing twelve months free cash flow of $3.20B. Inputs: FMP statements, estimates and quote.
How the stock reacts to earnings
EPS beat in 6 of the last 12 reports (2024–2026); the stock still fell the next session after 3 of those beats. Average first-session move: 4.6% either way.
- -2.0%Feb ’24
- +2.3%May ’24
- -0.3%Aug ’24
- +6.1%Nov ’24
- -3.0%Feb ’25
- -10.2%May ’25
- -18.9%Aug ’25
- -0.9%Nov ’25
- +6.6%Feb ’26
- +0.1%May ’26
- +0.3%Aug ’26
- -5.0%Nov ’26
Every report, with revenue and five-session moves
| Report | EPS | Revenue | Next session | 5 sessions |
|---|---|---|---|---|
| Miss | In line | -5.0% | -1.4% | |
| In line | Beat | +0.3% | +9.8% | |
| Beat | In line | +0.1% | +2.7% | |
| Miss | In line | +6.6% | +3.4% | |
| Beat | In line | -0.9% | -1.0% | |
| Beat | Beat | -18.9% | -19.0% | |
| Miss | Miss | -10.2% | -12.3% | |
| In line | Beat | -3.0% | -1.5% | |
| Beat | Beat | +6.1% | +6.5% | |
| Miss | Miss | -0.3% | -6.0% | |
| Beat | Beat | +2.3% | +7.2% | |
| Beat | In line | -2.0% | -1.4% |
Misses cost real money here: the average first-session move after a miss was -2.2%.
What management is saying differently
Management's own words on the Q3 FY2026 call () against Q2 FY2026 (). Analysts' questions are left out.
- New this call: “phase study”, “pivotal development”, “rare endocrinology” — none of them came up in Q2 FY2026.
- Gone quiet: “acute pain”, “endocrine diseases”, “iii study”, “prescription growth” — regular themes last call, absent this time.
The tone held steady from one call to the next; what changed is the subject matter, not the confidence.
Our track record on this stock
Since the score went from 98 to 90 while the share price moved -2.0% through .
The score has stayed in the Exceptional band across the stretch we have recorded; we grade each band change three months after it happens.
The crowd against our signals
- Analysts: 86% of 56 rate it a buy; the average target sits +8.2% from the price of $536.45.
- Last 90 days: 13 rating actions, every one a reaffirmation.
- Our signals: Exceptional band; strongest pillar Business Quality (93), weakest Valuation (39).
Here we and the crowd agree. Where we differ is on price: our Valuation reading is more cautious than the analysts' targets.
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · below the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
How to read these dates
Estimated dates can change.
Other perspectives
Council score for Vertex Pharmaceuticals (VRTX): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 19, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Vertex Pharmaceuticals (VRTX), and what does it report?
Short answer · as of
Vertex discovers, develops and markets therapies aimed at specific disease mechanisms, then reaches patients through specialty pharmacies, distributors, hospitals and clinics.
Research dated 2026-09-12.
Its reported revenue measures commercial product sales rather than the scientific breadth of its pipeline, and Trikafta and Kaftrio remain the dominant product line by a wide margin.
This is not a development-stage biotechnology company funded mainly by outside capital. An established cystic fibrosis franchise produces substantial profit and operating cash flow, which in turn finances research across pain, blood disorders, kidney disease, diabetes and other serious conditions.
What do the latest results show for Vertex Pharmaceuticals (VRTX)?
Research dated 2026-09-12.
The latest quarter brought a sharp sequential revenue rebound to the highest level in the reported series. Gross profit, operating income, net income and diluted earnings also increased, while research spending edged higher and selling and administrative expense rose more noticeably. Revenue exceeded the market estimate, although adjusted earnings landed just below it.
Management expects Casgevy and other newer products to carry higher production costs than the small-molecule cystic fibrosis portfolio. That mix shift does not explain the latest revenue increase, but it does explain why expanding beyond cystic fibrosis may add sales without matching the legacy franchise’s gross margin.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $3.44B Nov 2, 2026
- Latest report · revenue estimate
- $3.42B Nov 2, 2026
- Latest report · revenue vs estimate
- Above estimate Nov 2, 2026
- Latest report · EPS vs estimate
- Below estimate Nov 2, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Nov 2, 2026 | $3.44B | $3.42B | $4.7600 | $4.8200 |
| Aug 3, 2026 | $3.33B | $3.23B | $4.7300 | $4.7400 |
| May 4, 2026 | $2.99B | $2.99B | $4.4700 | $4.2400 |
| Feb 12, 2026 | $3.19B | $3.18B | $5.0300 | $5.1100 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 2 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $3.08B | $1.08B | $4.20 (diluted) |
| Q4 FY2025 | $3.19B | $1.19B | $4.65 (diluted) |
What are the financial strengths and risks for Vertex Pharmaceuticals (VRTX)?
Short answer
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-12.
Vertex combines high gross and operating margins with positive operating cash flow across every quarter shown. Cash and investments stand far above total debt, and the short-term liquidity balance has climbed through the latest reporting periods, leaving ample capacity for research, commercialization and strategic transactions.
The financial vulnerability is product concentration rather than funding pressure. If cystic fibrosis growth weakens before newer medicines become material, heavy research and commercial spending would bear on a narrower growth engine; rising Casgevy contribution could also dilute gross margin because its production economics are less favorable. The valuation already reflects substantial profitability, so weaker execution would matter even without balance-sheet stress.
Data-derived red flags
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
- Rich valuation — a P/E of 34.11 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.
What should you watch next at Vertex Pharmaceuticals (VRTX)?
Short answer · as of
The next earnings report is expected on Feb 11, 2027. The number it tests is the $18.16 EPS analysts carry for it.
Research dated 2026-09-12.
Watch whether overall product revenue keeps advancing as Alyftrek expands and Casgevy contributes more, rather than treating pipeline breadth as proof of commercial diversification. The next earnings release should also be tested against management’s expectation for gross margin near its recent level and operating expense near the upper end of guidance.
Cash conversion deserves equal attention: operating cash flow has remained strong but variable from period to period. Updated guidance around the announced transaction’s closing, along with the next periodic filing, should clarify whether the deal changes near-term revenue or expense expectations beyond the modest impact management currently anticipates.
How does Vertex Pharmaceuticals compare with its peers?
Short answer
Vertex Pharmaceuticals's score ranks 7th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
Vertex differs from many biotechnology peers because approved rare-disease medicines already support strong margins, durable cash generation and a net cash position large enough to fund an ambitious pipeline internally. It is therefore better understood as a profitable cystic fibrosis incumbent pursuing therapeutic expansion than as a collection of clinical-stage projects.
That maturity comes with an unusual concentration tradeoff. Trikafta and Kaftrio dominate revenue, while diversification through products such as Alyftrek and Casgevy introduces different commercial and manufacturing economics. Comparable drug developers may offer broader revenue mixes or greater pipeline dependence; Vertex couples financial resilience with a particularly concentrated commercial foundation.
| Company | Price | Market value | Score |
|---|---|---|---|
| $577.34 Nov 18, 2026 | $24.6B | 97 5-pillar Nov 18, 2026 | |
| $942.04 Nov 19, 2026 | $59.2B | 96 5-pillar Nov 18, 2026 | |
| $270.33 Nov 18, 2026 | $17.7B | 96 5-pillar Nov 18, 2026 | |
| $945.53 Nov 18, 2026 | $97.8B | 95 5-pillar Nov 18, 2026 | |
| $162.86 Nov 18, 2026 | $16.5B | 95 5-pillar Nov 18, 2026 | |
| $117.80 Nov 18, 2026 | $24.0B | 91 5-pillar Nov 18, 2026 | |
| Vertex Pharmaceuticals (VRTX) — this page | $536.45 | $136B | 90 |
| $47.12 Nov 18, 2026 | $113B | 87 5-pillar Nov 18, 2026 | |
| $39.43 Nov 18, 2026 | $174B | 87 5-pillar Nov 18, 2026 | |
| $59.56 Nov 18, 2026 | $122B | 85 5-pillar Nov 18, 2026 | |
| $80.06 Nov 19, 2026 | $102B | 81 5-pillar Nov 18, 2026 | |
| $100.72 Nov 18, 2026 | $129B | 81 5-pillar Nov 18, 2026 | |
| $48.58 Nov 18, 2026 | $97.4B | 77 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $350.00 – $665.00
- Consensus target
- $579.29
- Median target
- $608.00
- Revenue estimate
- $13.26B
- EPS estimate
- $18.16
Consensus record · Captured .
Measured against a quoted price of $536.45 (as of Nov 18, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 12, 2026
- Transactions
- 20
- Identified insiders
- 12
- Purchases
- 0
- Sales
- 10
- Other transactions
- 10
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held VRTX in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0.08% | $18.25M | Added +221.4% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Vertex Pharmaceuticals (VRTX)?
Common Questions About VRTX (Healthcare)
Research dated 2026-09-12; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
Why do Trikafta and Kaftrio matter so much to Vertex?
They account for the great majority of reported product revenue, making cystic fibrosis demand the main driver of current business performance. Alyftrek and other products are broadening the portfolio, but they have not displaced that dependence.
How could Casgevy change Vertex’s margin profile?
Casgevy carries higher production costs than Vertex’s small-molecule cystic fibrosis drugs. Greater contribution would diversify revenue while putting downward pressure on the blended gross margin unless offset elsewhere.
What role does Alyftrek play beside Trikafta and Kaftrio?
Alyftrek is reported as a distinct and meaningful product line, but it remains far smaller than Trikafta and Kaftrio. Its progress matters because it can extend Vertex’s cystic fibrosis franchise even as the company pursues diversification beyond that disease.
Can Vertex fund Casgevy and its broader pipeline without new borrowing?
Current finances provide substantial internal capacity: operating cash flow has stayed positive, while cash and investments comfortably exceed debt. Research spending remains heavy, but the balance sheet does not presently make borrowing the necessary source of pipeline funding.
What is the VRTX stock price today?
The last price recorded for Vertex Pharmaceuticals Incorporated (VRTX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the VRTX price target?
The analyst consensus price target for Vertex Pharmaceuticals Incorporated (VRTX), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Reviewed by Sedat ANAK, Founder and Editor-in-Chief, on 2026-11-07.
Sources: the source register lists the 44 figures on this page — 1 from SEC filings and earnings calls, 35 from Financial Modeling Prep (FMP), 5 with no recorded source, 2 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-12), by section of the research
ETFs that hold VRTX
Funds in our ETF coverage that list VRTX among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
